The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Am J Psychiatry 120:897-899, March 1964
doi: 10.1176/appi.ajp.120.9.897
© 1964 American Psychiatric Association
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by MILLER, M. H.
* Articles by FELLNER, C. H.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by MILLER, M. H.
* Articles by FELLNER, C. H.

A STUDY OF THE ANTIDEPRESSANT EFFECTS OF PARGYLINE

MILTON H. MILLER M.D., LEIGH M. ROBERTS M.D., , and CARL H. FELLNER M.D.1

1 Dept. of Psychiatry, Univ. of Wisconsin Medical School, Madison, Wisconsin.

The evaluation of antidepressant medication in an office practice setting is complicated by the somewhat unpredictable course of the illness, the long time interval before medications can become effective, and by the difficulty in weighing subjective findings. Our clinical impression, however, is that pargyline may demonstrate a low order of clinical effectiveness as an antidepressant agent. It would not appear to be as dependable or as effective as some of the other antidepressant medications which are available.

The low order of antidepressant effects may have some importance clinically in the use of pargyline as an anti-hypertensive drug since some other blood pressure reducing agents now in use in medical practice have a predilection for the production of depression. Further clinical study will be necessary to determine whether this inference holds. Importantly, physicians prescribing this medication for its antihypertensive effects should be aware of the fact that this is a monoamine oxidase inhibitor which must be prescribed with care. It should probably never be given along with other monoamine oxidase inhibitors or imipramine.







Get information about faster international access.

Privacy Policy

Copyright © 1964 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org